Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →Happiest Minds Technologies Limited — Q4 FY25
Happiest Minds delivered a strong FY25 with constant currency revenue growth of 25.6%, reaching $244M and crossing the INR 2,000 crore threshold.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Happiest Minds delivered a strong FY25 with constant currency revenue growth of 25.6%, reaching $244M and crossing the INR 2,000 crore threshold. Q4 constant currency growth was 1.1% QoQ and 27.9% YoY, impacted by a $1.5M bad debt provision from a U.S. government client. EBITDA margin for the year was 21.4%, within the guided 20%-22% range, despite ~INR 40 crore investments in GenAI and new sales. Management guided for healthy double-digit organic growth in FY26 and FY27, driven by 10 transformational initiatives including vertical reorganization, a dedicated GenAI business unit, and a new healthcare product expected by Q1 FY27. Key risks include delayed decision-making in manufacturing/retail and potential dilution from M&A earn-outs. The company remains confident in its growth trajectory despite industry headwinds.
हैप्पिएस्ट माइंड्स ने वित्त वर्ष 2025 में शानदार प्रदर्शन किया। कंपनी की कमाई (रेवेन्यू) में 25.6% की बढ़ोतरी हुई, जो 244 मिलियन डॉलर और 2,000 करोड़ रुपये से अधिक है। चौथी तिमाही में कमाई पिछली तिमाही से 1.1% और पिछले साल की इसी तिमाही से 27.9% बढ़ी, हालांकि एक अमेरिकी सरकारी ग्राहक से 1.5 मिलियन डॉलर का कर्ज न मिलने का असर पड़ा। पूरे साल का मुनाफा (EBITDA मार्जिन) 21.4% रहा, जो कंपनी के अनुमान (20%-22%) के अंदर है। कंपनी ने अगले दो सालों में अच्छी बढ़त का अनुमान लगाया है, जिसमें नई तकनीक (जनरेटिव AI) और स्वास्थ्य सेवा उत्पाद पर फोकस होगा। जोखिमों में विनिर्माण और खुदरा क्षेत्र में फैसलों में देरी शामिल है।
Promises0 met · 2 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Bad debt from U.S. government client
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Constant Currency Revenue Growth (FY25)
25.6%
+25.6pp YoY
Full-year constant currency growth, the best since IPO.
Net Promoter Score
63
N/A
Industry-leading NPS from customer satisfaction survey.
GenAI Revenue Contribution
2%
N/A
Direct GenAI revenue as a percentage of total revenue.
Total Headcount Added (FY25)
1,464
+28.3% YoY
Net new employees added during the fiscal year.
What Changed vs Last Quarter
NEW
Healthcare product launch by Q1 FY27
A revolutionary healthcare product based on bioinformatics is expected to be available for launch by Q1 FY27, with cash-positive operations from the first year.
NEW
Integrated organizational structure announcement in 4-6 weeks
A new integrated structure combining Happiest Minds, PureSoftware, and Aureus will be announced within 4-6 weeks.
UPDATED
Healthy double-digit organic growth in FY26 and FY27
Management expects organic growth to remain in double digits for the next two years, driven by transformational initiatives.
UPDATED
EBITDA margin guidance of 20%-22% maintained
The company reiterated its EBITDA margin range of 20%-22% for the foreseeable future.
DROPPED
FY25 constant currency revenue growth near 30%
Management aims to close FY25 with constant currency growth as close to 30% as possible, with Q4 expected to show strong sequential growth.
DROPPED
GenAI POCs to convert to revenue in FY26
Approximately 15 GenAI proof-of-concept projects are expected to convert into significant orders and projects in the next fiscal year.
NEW RISK
Bad debt from U.S. government client
A customer with U.S. government business reneged on payment, causing a $1.5M provision and revenue loss in Q4.
NEW RISK
Softness in manufacturing and retail verticals
Delayed decision-making and a wait-and-watch approach by clients in manufacturing and retail sectors pose a risk to growth.
NEW RISK
Potential dilution from M&A earn-outs
Better-than-expected performance of acquired entities leads to additional earn-out payments that hit the P&L as exceptional items.
RISK GONE
GenAI investment impacting margins
GenAI business unit is in investment mode, with $1.5M spent in nine months; margins could be pressured if revenue ramp-up is slower than expected.
RISK GONE
Attrition uptick
Attrition increased to 15.3% (seasonal), but if it persists, it could impact delivery and margins.
RISK GONE
Revenue concentration in BFSI
BFSI growth is strong, but over-reliance on one vertical could be a risk if sector spending slows.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q1 FY25, Q2 FY24, Q2 FY25, Q3 FY24
Management reiterated full-year revenue growth guidance of 30-35%, expecting Q4 to be stronger than Q3 due to large deal closures.
Mentioned in Q1 FY24, Q1 FY25, Q2 FY24, Q4 FY24
Management reiterated long-term target of $1 billion revenue by FY31, supported by acquisitions and organic growth.
Mentioned in Q1 FY25, Q2 FY24, Q2 FY25
Q3 typically has fewer working days due to vacations and client furloughs, which could impact sequential revenue growth.
Mentioned in Q3 FY25, Q4 FY24
Management aims to close FY25 with constant currency growth as close to 30% as possible, with Q4 expected to show strong sequential growth.
Mentioned in Q1 FY25, Q4 FY24
PureSoftware and Aureus contributed only 40 and 38 days respectively; full integration and realization of synergies may take 2-3 quarters, with potential margin dilution.
Fast read
Guidance and risk preview
Management expects organic growth to remain in double digits for the next two years, driven by transformational initiatives.
A customer with U.S.
View Risks →